Llaurado A, Garcia-Carmona C, Restrepo-Vera JL, Aleman J, Salvado M, Sanchez-Tejerina D, Sotoca J, Seoane JL, Lainez E, Gratacos-Vinola M, Vidal-Taboada JM, Fissolo N, Comabella M, Raguer N, Juntas-Morales R
Usefulness of serum neurofilament light chain in chronic inflammatory demyelinating polyradiculoneuropathy.
J Neurol Sci. 2025 Mar 15;470:123397. doi: 10.1016/j.jns.2025.123397. Epub 2025 Jan 18.
DOI: 10.1016/j.jns.2025.123397
IF: 3.7
RESEARCH GROUPS
Peripheral Nervous System
15
Number of publications
46.67
%
% Q1
20.00
%
% D1
40.00
%
% Leadership
16.67
%
% Female Leadership
1.92
CROWN (2021-2025)
18.18
%
HCP10% (2021-2025)
66.67
%
% Open access
33.33
%
% International Collaboration
3
Highly cited papers / HCP 1% (2021-2025)
2
Publications in high-IF journals with high Altmetric scores
3
Number of Ongoing Projectes (total)
0
International ongoing projects
0
Number of New projects (total)
0
International new projects
25
Number of Active clinical Trials
13
Number of New Clinical Trials
0
Number of Theses
The group’s main line of research is translational and consists of developing biomarkers for various neuromuscular diseases with the aim of implementing them in clinical practice. The objective is to develop clinical, biological, and neurophysiological tools that will allow us to practice precision medicine. We currently have two funded projects (AES and Luzon Foundation) for the development of a panel of biological biomarkers in ALS patients. We are coordinating this study, which involves other centers such as the Hospital of Lleida, the 12 de Octubre Hospital, and the University Hospital of Montpellier. Furthermore, we also have ongoing biomarker projects for other neuromuscular diseases (Myasthenia gravis, Guillain-Barré, CIDP, etc.) thanks to competitive grants awarded by the pharmaceutical industry. Finally, the group is also developing new genetic diagnostic techniques (Exome sequencing, RNA-seq, and genome sequencing) applied to patients without a definitive diagnosis.
CORE/MISSIONS
- Innovative & Advanced Therapies
- Rare Diseases
PROGRAMS
TEAM
Group Leader
Raul Juntas Morales
Principal Investigator (PI)
Raul Juntas Morales
Researchers
Jose Manuel Vidal Taboada, Maria Salvadó Figueres, David Ovelleiro Fraile, Silvia Sánchez Martín, Sara Marmolejo Martínez-Artesero, Elena Lainez, Margarida Gratacos
PhD Students
Daniel Sánchez Tejerina San José, Arnau Llauradó Gayete, Lidia Giramé Rizzo, Jose Alemany Diez, Juan Luis Restrepo Vera
Lab Technicians
Paula Sánchez Álvarez
SELECTED PUBLICATIONS
Llaves-Lopez A, Micoli E, Belmonte-Mateos C, Aguilar G, Alba C, Marsal A, Pulido-Salgado M, Rabaneda-Lombarte N, Sola C, Serratosa J, Vidal-Taboada JM, Saura J
Human Microglia-Like Cells Differentiated from Monocytes with GM-CSF and IL-34 Show Phagocytosis of alpha-Synuclein Aggregates and C/EBPbeta-Dependent Proinflammatory Activation.
Mol Neurobiol. 2025 Jan;62(1):756-772. doi: 10.1007/s12035-024-04289-z. Epub 2024 Jun 20.
DOI: 10.1007/s12035-024-04289-z
IF: 4.6
Lainez E, Llaurado A, Gratacos-Vinola M, Seoane JL, Trallero-Araguas E, Arino H, Roca-Herrera M, Juntas R, Raguer N
Electrophysiological findings in immune checkpoint inhibitor-related neuromuscular events.
Clin Neurophysiol. 2025 Aug 26;179:2110989. doi: 10.1016/j.clinph.2025.2110989.
DOI: 10.1016/j.clinph.2025.2110989
IF: 3.6
Bensimon G, Leigh PN, Tree T, Malaspina A, Payan CA, Pham HP, Klaassen P, Shaw PJ, Al Khleifat A, Amador MDM, Attarian S, Bell SM, Beltran S, Bernard E, Camu W, Corcia P, Corvol JC, Couratier P, Danel V, Debs R, Desnuelle C, Dimitriou A, Ealing J, Esselin F, Fleury MC, Gorrie GH, Grapperon AM, Hesters A, Juntas-Morales R, Kolev I, Lautrette G, Le Forestier N, McDermott CJ, Pageot N, Salachas F, Sharma N, Soriani MH, Sreedharan J, Svahn J, Verber N, Verschueren A, Yildiz O, Suehs CM, Saker-Delye S, Muller C, Masseguin C, Hajduchova H, Kirby J, Garlanda C, Locati M, Zetterberg H, Asselain B, Al-Chalabi A
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.
Lancet. 2025 May 9:S0140-6736(25)00262-4. doi: 10.1016/S0140-6736(25)00262-4.
DOI: 10.1016/S0140-6736(25)00262-4
IF: 98.4
Llaurado A, Pinos T, Codina-Sola M, Martinez-Saez E, Restrepo-Vera JL, Salvado M, Sanchez-Tejerina D, Sotoca J, Munoz P, Rovira-Moreno E, Buyukdereli L, Garcia-Arumi E, Vidal-Taboada JM, Ovelleiro D, Juntas-Morales R
Expanding the clinical phenotype and understanding the biochemical consequences of Muscle Glycogen Synthase Deficiency (GSD0B).
Mol Genet Metab. 2025 Jul;145(3):109140. doi: 10.1016/j.ymgme.2025.109140. Epub 2025 May 18.
DOI: 10.1016/j.ymgme.2025.109140
IF: 3.7
SELECTED PROJECTS
Desarrollo e implementación de un nuevo panel de biomarcadores clínicos y moleculares para pronosticar la progresión y la supervivencia en pacientes con ELA
Principal Investigator: Raul Juntas Morales
Agency: Instituto de Salud Carlos III
Funding: 190,000 €
Period: 2024 - 2026
Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients'.
Principal Investigator: Raul Juntas Morales
Agency: Projecte FCO.LUZON/PROJECTES/2024/JUNTAS, finançat per Fundación Francisco Luzón
Funding: 160,000 €
Period: 2024-2027
Biomarcadores para el diagnóstico y pronóstico del Síndrome de Guillain-Barré
Principal Investigator: Raul Juntas Morales
Agency: GRIFOLS
Funding: 30,000 €
Period: 2024-2027
Biomarcadores para el seguimiento y pronóstico de la Miastenia Gravis
Principal Investigator: Raul Juntas Morales
Agency: ARGENX
Funding: 70,000 €
Period: 2024-2027
Biomarcadores clínicos, moleculares y neurofisiológicos para el diagnóstico y seguimiento de la polineuropatía desmielinizante inflamatoria crónica
Principal Investigator: Raul Juntas Morales
Agency: CSL BEHRING
Funding: 30,000 €
Period: 2023-2026
PATENTS
DISSEMINATION ACTIVITIES
JORNADA DE PACIENTES ELA
Place: Hospital Vall d'Hebron
Date: 21/06/2025
Brief: scientific dissemination for patients
JORNADA ANUAL DE LA ASOCIACION FHSD SPAIN
Place: MADRID
Date: 5 mayo 2025
Brief: scientific dissemination for patients
